focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,110.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Time to start some defensive rotation?

Wed, 31st Mar 2021 12:57

* European shares up 0.2%

* Deliveroo flops on market debut

* DAX hovers around 15,000 points

* Eyes on Biden infrastructure plan

March 31 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

TIME TO START SOME DEFENSIVE ROTATION? (1157 GMT)

It’s not easy to make the right choice in the stock markets,
amid cyclicals increasingly stretched valuations versus
defensives and expectations of stronger growth and inflation,
coupled with higher bond yields.

Morgan Stanley analysts see “potential catalysts for a
bigger tactical defensive rotation later in the year,” while
they are wary of “rotating too hard just yet.”

“Our expectation for continued strong growth data, prevents
us from wanting to get too defensive just yet, but we think it
makes sense to start to reduce the size of our underweight
stance,” they say in a research note.

Bottom line, they upgrade pharma stocks to neutral, which
they say trade “at a rare PE discount to the wider market,”
while downgrading to neutral consumer services and transport,
“where valuations look increasingly rich.”

BofA says cyclicals “are already pre-pricing an improvement
in macro momentum.”

But “if PMIs rebound to unusually strong levels by Q3 and
bond yields continue to rise, as we expect, this would imply a
further 15% upside for cyclicals versus defensives by Q3,” it
adds. In the table below BofA's forecast overview.

(Stefano Rebaudo)

*****

EUROPE: IN THE MOOD FOR LOVE (1130 GMT)

This has been a fine quarter for European equities which are
set to exit Q1 with a rise of over 8%.

Worth noting that for the first time since Q3 2019, the
STOXX 600 has outperformed the S&P 500 which is up 'only' 5.4%.

Europe, however, remains unloved, Barclays analysts point
out.

"Despite their good relative performance ytd, European
equities remain ignored by global investors", the bank's
analysts write.

"We believe that improving vaccine rollout later this year
and reopening could be the triggers for the region to see
inflows again", they argue, adding that because Europe is
overweight on popular value stocks, it could benefit from
managers rotating their portfolios.

(Julien Ponthus)

*****

NEW RECORD HIGH FOR AMSTERDAM (1018 GMT)

There's been a lot of chatter about the 15,000 points
snatched by the DAX but other indexes in Europe are also
enjoying the end of Q1.

Amsterdam's AEX has just reached a record high of 703.44
points, its highest level since September 2000!

The STOXX 600 is also very close to testing unchartered
highs, just 2 points below its February 2020 record of 433.90
points.

Here's the AEX since 1995:

(Julien Ponthus)

*****

DELIVEROO UNDERDELIVERS (0832 GMT)

Horrible, disastrous... there's no shortage of adjectives
out there to describe the fiasco of Deliveroo which a few
minutes after its London debut saw its shares hit a 271 pence
low, 30% below their 390 pence IPO price tag.

Here is a round up of comments we got so far.

Russ Mould, Investment Director at AJ Bell: "How could a
company that was valued at $3 billion in November, $5 billion in
January, be magically worth 8-9 billion in March - particularly
when according to its own statements it was potentially
requirement in need of emergency funding last year. I guess the
question now is does this mean that we’re about to enter a more
difficult period for these IPOs that loss-making companies
become with very high valuations, which would be an interesting
shift of tone".

Angelo Meda, portfolio manager at Banor SIM: "The wind has
turned on all growth stocks. I don't know if this is a stock
that will recover anytime soon. We stayed out of the IPO because
of concerns over valuation and regulation. Until there is
clarity on riders' rights it will be difficult to invest in this
sector".

Connor Campbell, analyst at Spreadex: "Deliveroo has been
able to grow to the point of launching on the stock market in
part thanks to the exploitation of its workers. Now, said
exploitation is one of the main reasons behind its sour start to
life as a public company, with multiple leading fund managers
expressing concern over its labour practices. It is maybe a case
of a perfectly zeitgeisty company in one sense – Deliveroo is a
primary pandemic beneficiary – coming of age in the wrong
moment, i.e. in the era of ostensible environmental, social and
corporate governance".

James Athey, investment director at Aberdeen Standard
Investments: "The number of institutions lining up to say no on
ESG grounds always looked like it was going to make it a tricky
debut".

Stephane Ekolo global equity strategist at Tradition: "It
stings. Some UK asset managers had warned about work conditions
and the business model and had flagged regulation risks".

Neil Wilson, analyst at Markets.com:
"Chiefly though it reflects the fact that even pricing the IPO
at the bottom of the range, Deliveroo was demanding too high a
price tag for a loss-making delivery platform in a very
competitive space with a questionable path to profitability. The
books were covered, it was just plain mis-priced".

(Julien Ponthus, Danilo Masoni, Elizabeth Howcroft)

*****

DAX RESISTS ABOVE 15K, DELIVEROO FLOPS (0726 GMT)

European shares are off to a muted start this morning with
the main regional benchmark trading just above parity and no
sector taking the lead in either direction.

Germany's DAX is flat but it's managing to hold above the
15,000 points mark it breached yesterday for the first time.

In London, Deliveroo delivered a disappointing debut,
falling as much as 30% from its IPO prices in the first minutes
of life.

Elsewhere, a couple of downgrades are making videogame maker
CD Projekt the biggest faller on the STOXX, down 11%.

Here's your snapshot.

(Danilo Masoni)

*****

SO LONG Q1, U.S. LEADS GOING INTO Q2 (0702 GMT)

The first quarter draws to a close and what a quarter it's
been: an 82 basis-point surge in U.S. Treasury yields on a
stimulus boost the size of which few would have anticipated, a
25% oil price jump, amateurs taking on seasoned hedge funds and
big banks taking big hits from trouble at hedge funds.

But having added some $2.6 trillion in value over the first
three months, MSCI's global equity index is ending the quarter
in a defensive mood. Asian stocks, outside Japan, are down 0.3%,
the Nikkei shed 0.9% and futures point to a weak open for
European bourses. Wall Street futures are flat.

The outlier is the dollar, riding at fresh one-year peaks
against the yen and at multi-month highs versus other major
currencies.

Its gains come as the United States races ahead of the rest
in terms of vaccinations, economic growth and the sheer size of
government spending. And U.S. President Joe Biden will outline
later on Wednesday how he intends to pay for a $3-$4 trillion
infrastructure plan.

That kind of spending will benefit the rest of the world
too; the IMF will raise global growth forecasts for 2021 and
2022, Managing Director Kristalina Georgieva said on Tuesday.

But the Biden plan, and the likelihood of more debt
issuance, also explains this week's bond selloff that's taken
10-year Treasury yields towards 14-months highs at around 1.78%.

In UK markets, trading starts in food delivery company
Deliveroo, whose shares will list at 390 pence each, valuing the
company at 7.6 billion pounds ($10.5 billion). It's the biggest
London IPO for a decade, yet its valuations lag continental
peers Just Eat and Delivery Hero.

Key developments that should provide more direction to
markets on Wednesday:

- Euro zone flash inflation data due; data on Tuesday showed
German inflation topped ECB target in March.

- China's manufacturing expands at the quickest pace in
three months in March.

- Britain's economy grows a stronger-than-expected 1.3% in
Q4.

- Hitachi to buy U.S. software firm GlobalLogic Inc for $9.6
billion.

- Germany to limit the use of AstraZeneca COVID-19
vaccine to people aged 60 and above

- OPEC+ oil producing group is concerned that uncertainties
may impact the recovery in oil demand

- Gold set for worst quarter since 2016.

- U.S. ADP national unemployment, Chicago PMI data due.

- Sweden's H&M swings to Q1 loss

(Dhara Ranasinghe)

*****

DELIVEROO FOR BREAKFAST (0625 GMT)

Today is Deliveroo day!

The food delivery company is making its debut on the London
stock market this morning in what is set to be the biggest IPO
since Glencore back in 2011.

Now, with the Nasdaq easing 0.1% yesterday and tech/growth
shares under pressure, the context is perhaps not ideal.

The S&P technology sector ended down 1% and was
the biggest drag on the S&P 500.

The Nasdaq is on track for its first monthly loss since
November with 10-year U.S. Treasury yields rising
to 1.77%, their highest since Jan. 22.

European futures are also in the red, losing about 0.3% at
the time of writing.

(Julien Ponthus)

*****

More News
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more
19 Feb 2024 08:36

TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data

(Alliance News) - AstraZeneca PLC on Monday announced new study data and a new approval for its cancer medication Tagrisso.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.